总时间（秒）：20.44
问答时间（秒）：18.59

{
    "functional_evidence_assessment": [
        {
          "variant_id": {
            "Gene": "LRRK2",
            "Protein_Change": {
              "ref": "Wild-type",
              "alt": "",
              "position": ""
            },
            "variant_string_id": "LRRK2_WT"
          },
          "functional_evidence_aim": "Pathogenic",
          "assessment_steps": [
            {
              "step_name": "Step 1: Define the disease mechanism",
              "extracted_paper_info": "The paper clearly defines that LRRK2 is a stress responsive protein scaffold mediating the regulation of MAPK pathways, and its mutation leads to the onset of parkinsonian symptoms. Specifically, wild-type LRRK2 enhances tolerance of HEK293 and SH-SY5Y cells towards H2O2-induced oxidative stress through activation of the ERK pathway.",
              "judgment": "Yes",
              "reasoning": "The paper explicitly states that LRRK2 regulates MAPK pathways, and wild-type LRRK2 enhances cell tolerance towards oxidative stress via the ERK pathway."
            },
            {
              "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
              "extracted_paper_info": "The study uses a cell phenotype rescue assay, which effectively models or reflects the disease pathogenesis/mechanism defined in Step 1.",
              "judgment": "Yes"
            },
            {
              "step_name": "Step 3: Evaluate validity of specific instances of assays",
              "sub_steps": [
                {
                  "sub_step_name": "3a. Basic Controls and Replicates",
                  "questions": [
                    {
                      "question": "Were basic controls included for this assay? Specifically, were 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                      "answer": "Yes"
                    },
                    {
                      "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                      "answer": "Yes"
                    }
                  ]
                },
                {
                  "sub_step_name": "3c. Variant Controls",
                  "questions": [
                    {
                      "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls?",
                      "answer": "Yes"
                    }
                  ]
                },
                {
                  "sub_step_name": "4a. Statistical Analyses",
                  "questions": [
                    {
                      "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                      "answer": "No"
                    }
                  ]
                },
                {
                  "sub_step_name": "4b. No OddsPath Calculation",
                  "questions": [
                    {
                      "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                      "answer": "At least 11"
                    }
                  ]
                },
                {
                  "sub_step_name": "4c. Correlate OddsPath",
                  "questions": []
                }
              ]
            }
          ],
          "functional_evidence_strength": "Max PS3_moderate"
        },
        {
          "variant_id": {
            "Gene": "LRRK2",
            "Protein_Change": {
              "ref": "",
              "alt": "Mutant",
              "position": ""
            },
            "variant_string_id": "LRRK2_MUT"
          },
          "functional_evidence_aim": "Benign",
          "assessment_steps": [
            {
              "step_name": "Step 1: Define the disease mechanism",
              "extracted_paper_info": "The paper clearly defines that LRRK2 is a stress responsive protein scaffold mediating the regulation of MAPK pathways, and its mutation leads to the onset of parkinsonian symptoms. Specifically, wild-type LRRK2 enhances tolerance of HEK293 and SH-SY5Y cells towards H2O2-induced oxidative stress through activation of the ERK pathway.",
              "judgment": "Yes"
            },
            {
              "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
              "extracted_paper_info": "The study uses a cell phenotype rescue assay, which effectively models or reflects the disease pathogenesis/mechanism defined in Step 1.",
              "judgment": "Yes"
            },
            {
              "step_name": "Step 3: Evaluate validity of specific instances of assays",
              "sub_steps": [
                {
                  "sub_step_name": "3a. Basic Controls and Replicates",
                  "questions": [
                    {
                      "question": "Were basic controls included for this assay? Specifically, were 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                      "answer": "Yes"
                    },
                    {
                      "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                      "answer": "Yes"
                    }
                  ]
                },
                {
                  "sub_step_name": "3c. Variant Controls",
                  "questions": [
                    {
                      "question": "Were variant controls used in the assay for this variant? Specifically, were known benign variants used as controls?",
                      "answer": "Yes"
                    }
                  ]
                },
                {
                  "sub_step_name": "4a. Statistical Analyses",
                  "questions": [
                    {
                      "question": "Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant?",
                      "answer": "No"
                    }
                  ]
                },
                {
                  "sub_step_name": "4b. No OddsPath Calculation",
                  "questions": [
                    {
                      "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                      "answer": "At least 11"
                    }
                  ]
                },
                {
                  "sub_step_name": "4c. Correlate OddsPath",
                  "questions": []
                }
              ]
            }
          ],
          "functional_evidence_strength": "Max BS3_moderate"
        }
    ]
}